📊 NOTV Key Takeaways
Is Inotiv, Inc. (NOTV) a Good Investment?
Inotiv demonstrates severe operational distress with persistent negative profitability despite modest revenue growth of 4.5% YoY. The company is bleeding cash with negative operating and free cash flow while carrying unsustainable leverage of 3.72x debt-to-equity, leaving minimal liquidity cushion with a critical 0.30x current ratio.
Fundamentals indicate persistent losses, negative free cash flow, and acute liquidity stress (0.30x current ratio) alongside negative interest coverage. Modest 4.5% revenue growth and improved EPS loss are insufficient against high leverage (3.72x D/E) and weak margins. Without swift, sustained cash generation or balance sheet repair, distress or dilutive actions are likely.
Why Buy Inotiv, Inc. Stock? NOTV Key Strengths
- Revenue growth of 4.5% YoY demonstrates continued customer demand in commercial research services
- Gross margin of 24.9% indicates reasonable pricing power and cost structure at the production level
- Marginal improvement in diluted EPS of 49.6% YoY suggests some operational stabilization efforts
- Modest YoY revenue growth (+4.5%)
- Positive gross profit ($30.16M) that could support future margin recovery
- Shareholders' equity remains positive (assets exceed liabilities)
NOTV Stock Risks: Inotiv, Inc. Investment Risks
- Operating margin of -13.5% and net margin of -23.5% indicate fundamental unprofitability and value destruction at scale
- Dangerously low liquidity with current ratio of 0.30x and quick ratio of 0.22x creates imminent solvency concerns
- Extreme leverage with $405.8M long-term debt against $109M equity and negative interest coverage of -3.8x indicates inability to service debt obligations from operations
- Negative operating cash flow of -5.4M and free cash flow of -10.6M demonstrate cash burn with no organic cash generation
- ROE of -26.0% and ROA of -3.9% show shareholder capital is being destroyed
- Severe liquidity shortfall (current 0.30x, quick 0.22x)
- High leverage with negative interest coverage (-3.8x) increasing refinancing risk
- Continued operating and net losses with negative FCF (-8.8% margin)
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Operating margin improvement trajectory toward breakeven
- Debt reduction progress and refinancing capability
- Current ratio improvement toward 1.0x minimum threshold
- Operating cash flow
- Current ratio
Inotiv, Inc. (NOTV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
NOTV Profit Margin, ROE & Profitability Analysis
NOTV vs Healthcare Sector: How Inotiv, Inc. Compares
How Inotiv, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inotiv, Inc. Stock Overvalued? NOTV Valuation Analysis 2026
Based on fundamental analysis, Inotiv, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inotiv, Inc. Balance Sheet: NOTV Debt, Cash & Liquidity
NOTV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inotiv, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.10 indicates the company is currently unprofitable.
NOTV Revenue Growth, EPS Growth & YoY Performance
NOTV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $119.9M | -$27.6M | $-0.83 |
| Q3 2025 | $105.8M | -$14.9M | $-0.51 |
| Q2 2025 | $119.0M | -$14.9M | $-0.44 |
| Q1 2025 | $119.9M | -$15.4M | $-0.60 |
| Q3 2024 | $105.8M | $1.8M | $0.07 |
| Q2 2024 | $119.0M | -$10.0M | $-0.39 |
| Q1 2024 | $122.8M | -$15.4M | $-0.60 |
| Q3 2023 | $157.5M | $1.8M | $0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inotiv, Inc. Dividends, Buybacks & Capital Allocation
NOTV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inotiv, Inc. (CIK: 0000720154)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NOTV
What is the AI rating for NOTV?
Inotiv, Inc. (NOTV) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NOTV's key strengths?
Claude: Revenue growth of 4.5% YoY demonstrates continued customer demand in commercial research services. Gross margin of 24.9% indicates reasonable pricing power and cost structure at the production level. ChatGPT: Modest YoY revenue growth (+4.5%). Positive gross profit ($30.16M) that could support future margin recovery.
What are the risks of investing in NOTV?
Claude: Operating margin of -13.5% and net margin of -23.5% indicate fundamental unprofitability and value destruction at scale. Dangerously low liquidity with current ratio of 0.30x and quick ratio of 0.22x creates imminent solvency concerns. ChatGPT: Severe liquidity shortfall (current 0.30x, quick 0.22x). High leverage with negative interest coverage (-3.8x) increasing refinancing risk.
What is NOTV's revenue and growth?
Inotiv, Inc. reported revenue of $120.9M.
Does NOTV pay dividends?
Inotiv, Inc. does not currently pay dividends.
Where can I find NOTV SEC filings?
Official SEC filings for Inotiv, Inc. (CIK: 0000720154) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NOTV's EPS?
Inotiv, Inc. has a diluted EPS of $-0.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NOTV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Inotiv, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NOTV stock overvalued or undervalued?
Valuation metrics for NOTV: ROE of -26.0% (sector avg: 15%), net margin of -23.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NOTV stock in 2026?
Our dual AI analysis gives Inotiv, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NOTV's free cash flow?
Inotiv, Inc.'s operating cash flow is $-5.4M, with capital expenditures of $5.2M. FCF margin is -8.8%.
How does NOTV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -23.5% (avg: 12%), ROE -26.0% (avg: 15%), current ratio 0.30 (avg: 2).
Is Inotiv, Inc. carrying too much debt?
NOTV has a debt-to-equity ratio of 3.72x, which is above the Healthcare sector average of 0.6x. Combined with a current ratio below 1, this warrants careful monitoring of the balance sheet.